Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | FPR2 | P25090 | 8/20 | 0.35 |
| ▸ | FPR3 | P25089 | 6/20 | 0.35 |
| ▸ | NAAA | Q02083 | 1/20 | 0.35 |
| ▸ | HPD | P32754 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26081071 | 0.83 | KDM4E (0.47) | USP2TSHR | |
| SCHEMBL10192218 | 0.81 | FPR2 (0.48) | USP2TSHRP2RX7FPR2PROKR1 | |
| SCHEMBL10192232 | 0.81 | FPR2 (0.48) | USP2TSHRP2RX7FPR2PROKR1 | |
| SCHEMBL26081049 | 0.77 | RORC (0.38) | USP2TSHRP2RX7 | |
| SCHEMBL10192225 | 0.76 | ALDH1A1 (0.44) | USP2TSHR | |
| SCHEMBL10191864 | 0.76 | ALDH1A1 (0.44) | USP2TSHR | |
| SCHEMBL18229254 | 0.72 | DGAT1 (0.46) | CYP3A4CYP2C9CYP2C19PYCR1PDPK1 | |
| SCHEMBL1773425 | 0.72 | GRIN2D (0.48) | USP2TSHR | |
| SCHEMBL17997260 | 0.71 | DGAT1 (0.37) | CYP3A4CYP2C9CYP2C19L3MBTL1KDM1A | |
| SCHEMBL3635802 | 0.69 | DGAT1 (0.38) | CYP3A4CYP2C9CYP2C19L3MBTL1KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312522-A1 | CYP46A1 INHIBITORS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2023-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312522-A1 | CYP46A1 INHIBITORS AND METHODS OF USE THEREOF | CYP46A1, CYP26A1, CYP4A22 | CYP3A4 26/4885CYP2C9 35/4885CYP2C19 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.